RP collaboration funding announced

Article

The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).

The National Neurovision Research Institute (NNRI) in the US and Adeona Pharmaceuticals Inc. have announced a collaboration to investigate the oral drug flupirtine in the treatment of retinitis pigmentosa (RP).

NNRI will fund preclinical trials of flupirtine, which has been administered to approximately 27 patients across Europe for five years to treat RP, in several animal models at the Bascom Palmer Eye Institute, Miami, Florida, US.

If the preclinical trial outcomes are positive, Adeona and NNRI will potentially move on to clinical testing.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.